FR3119767B1 - Composition pour renforcer le système immunitaire - Google Patents

Composition pour renforcer le système immunitaire Download PDF

Info

Publication number
FR3119767B1
FR3119767B1 FR2101595A FR2101595A FR3119767B1 FR 3119767 B1 FR3119767 B1 FR 3119767B1 FR 2101595 A FR2101595 A FR 2101595A FR 2101595 A FR2101595 A FR 2101595A FR 3119767 B1 FR3119767 B1 FR 3119767B1
Authority
FR
France
Prior art keywords
composition
strengthen
immune system
relates
immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2101595A
Other languages
English (en)
Other versions
FR3119767A1 (fr
Inventor
Marie Lapios
Jean-Luc Pougnas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NMC Lab SAS
Original Assignee
NMC Lab SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NMC Lab SAS filed Critical NMC Lab SAS
Priority to FR2101595A priority Critical patent/FR3119767B1/fr
Priority to EP22708880.4A priority patent/EP4294383A1/fr
Priority to PCT/EP2022/054115 priority patent/WO2022175470A1/fr
Publication of FR3119767A1 publication Critical patent/FR3119767A1/fr
Application granted granted Critical
Publication of FR3119767B1 publication Critical patent/FR3119767B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition comprenant au moins de l’acide élénolique et au moins un agent acidifiant. L’invention a également pour objet une telle composition pour son utilisation comme médicament ou complément alimentaire, en particulier pour renforcer l’immunité d’un être humain ou d’un animal.
FR2101595A 2021-02-18 2021-02-18 Composition pour renforcer le système immunitaire Active FR3119767B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR2101595A FR3119767B1 (fr) 2021-02-18 2021-02-18 Composition pour renforcer le système immunitaire
EP22708880.4A EP4294383A1 (fr) 2021-02-18 2022-02-18 Composition pour renforcer le systeme immunitaire
PCT/EP2022/054115 WO2022175470A1 (fr) 2021-02-18 2022-02-18 Composition pour renforcer le systeme immunitaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2101595A FR3119767B1 (fr) 2021-02-18 2021-02-18 Composition pour renforcer le système immunitaire
FR2101595 2021-02-18

Publications (2)

Publication Number Publication Date
FR3119767A1 FR3119767A1 (fr) 2022-08-19
FR3119767B1 true FR3119767B1 (fr) 2023-09-08

Family

ID=75278236

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2101595A Active FR3119767B1 (fr) 2021-02-18 2021-02-18 Composition pour renforcer le système immunitaire

Country Status (3)

Country Link
EP (1) EP4294383A1 (fr)
FR (1) FR3119767B1 (fr)
WO (1) WO2022175470A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737550A (en) * 1971-10-28 1973-06-05 Upjohn Co A method for treating influenza viral infections
AU4139196A (en) * 1994-11-07 1996-05-31 William R. Fredrickson Method and composition for antiviral therapy
US6165475A (en) 1998-07-23 2000-12-26 Creagri, Inc. Water-soluble extract from olives
KR100878549B1 (ko) * 2007-03-06 2009-01-14 아메리덴 인터내셔날 인코포레이티드 가공된 올리브 잎 추출물
JP5138341B2 (ja) * 2007-11-07 2013-02-06 日本メナード化粧品株式会社 抗アレルギー剤
ITMI20110941A1 (it) * 2011-05-25 2012-11-26 Phenofarm S R L Processo di produzione di un fito-estratto da acque di vegetazione esanse olearie
JP5730837B2 (ja) * 2012-11-05 2015-06-10 一丸ファルコス株式会社 メラニン生成抑制剤、保湿剤、美白化粧料、美容飲食品
ITMI20131815A1 (it) 2013-10-31 2015-05-01 Fattoria La Vialla Di Gianni Anton Io E Bandino L Uso antinfiammatorio di fitocomplessi liquidi da olive
GR1008734B (el) 2014-11-26 2016-04-05 ΚΡΕΤΑ ΦΑΡΜ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ με δ.τ. "ΚΡΕΤΑ ΦΑΡΜ Α.Β.Ε.Ε." Υδατικο εκχυλισμα ελιας με μεταβολικες και καρδιο-προστατευτικες ιδιοτητες.
US10469821B2 (en) 2016-06-17 2019-11-05 Altek Semiconductor Corp. Stereo image generating method and electronic apparatus utilizing the method
US20170367995A1 (en) 2016-06-23 2017-12-28 Allevium Therapeutics, Inc. Treatment of early stage parkinson's disease with a hydroxytyrosol-containing polyphenol formulation

Also Published As

Publication number Publication date
WO2022175470A1 (fr) 2022-08-25
EP4294383A1 (fr) 2023-12-27
FR3119767A1 (fr) 2022-08-19

Similar Documents

Publication Publication Date Title
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
TN2010000239A1 (fr) Composition pour l'alimentation humaine et/ou animale ses utilisations, levures
MA33993B1 (fr) Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r)
MA41067B1 (fr) Composition comportant de la chitine et des protéines digestibles
MA45562B1 (fr) Préparation pharmaceutique liquide stable
MA33592B1 (fr) Formulations pharmaceutiques hautement concentrées
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
EP4238420A3 (fr) Compositions de protéines de lactosérum, procédés et utilisations
ATE271769T1 (de) Flexibler milchschlauch für eine automatische melkanlage
FR3119767B1 (fr) Composition pour renforcer le système immunitaire
FR3081090B1 (fr) Probiotique pour volaille
MA38902B1 (fr) Olives conditionnées faiblement acides et sans saumure
FR3089094B1 (fr) Protéine de légumineuse soluble
FR2992861A1 (fr) Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
MA45890A1 (fr) Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
DE60218636D1 (de) Antikörper zur vorbeugung und behandlung von e. coli aeec krankheiten
MA38699B1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
DK1095572T3 (da) Anvendelse af en iodholdig forbindelse til fremsilling af et ioderet födevareprodukt til forhindring af tilstande forårsaget af skjoldbruskkirtlens dysfunktioner
MX2021002803A (es) Marcadores utiles en estrategias de enriquecimiento para el tratamiento de osteoartritis.
FR2868318B1 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih
FR3092994B1 (fr) Utilisation de peptides cycliques fongiques de type destruxine comme agents antibactériens actifs contre Clostridium perfringens
MA41102A (fr) Compositions contenant de la curcumine à biodisponibilité améliorée
JP5298941B2 (ja) 飲料
FR3078257B1 (fr) Utilisation cosmetique d'un hydrolat de sarriette citronnee pour ameliorer la fonction barriere de la peau
FR3085825B1 (fr) Huile de microorganismes riche en acide docosahexaenoique

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220819

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4